Of course, it is more complicated, with other cofactors involved, but that is the foundation
68, col
Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH. Full data from the phase III trial will be presented at the American Diabetes Associations (ADA) 2026 Scientific Sessions in June
Here is the full ingredient list
Obesity (Silver Spring, Md.), 10.1002/oby.24336
Daniel has also written for Diabetes Research Institute, dLife, diaTribe, Healthline, CareDx, Pendulum Therapeutics, and Hero Bread